The FDA Just Sent 30 Warning Letters to GLP-1 Telehealth Companies — Here's What They Found

On March 3, 2026, the FDA dropped the largest single enforcement action in GLP-1 telehealth history: 30 warning letters to telehealth companies for making false or misleading claims about compounded GLP-1 products on their websites.

This wasn't a first warning. It was the second wave. The agency has now sent more warning letters to pharmaceutical and telehealth firms in six months than over the entire preceding decade. Commissioner Marty Makary put it bluntly: "It's a new era."

What the FDA Actually Found

The violations fell into two primary categories, both rooted in how telehealth companies describe their products to consumers:

1. Implying Sameness with FDA-Approved Products

Many telehealth platforms marketed compounded semaglutide and tirzepatide in ways that blurred the distinction between their products and FDA-approved medications like Wegovy, Ozempic, Zepbound, and Mounjaro. The FDA's position is clear: compounded drugs are not FDA-approved, are not generics, and have not undergone the same safety, efficacy, and quality review.

2. Obscuring Product Sourcing

Some platforms marketed compounded medications under their own brand name or trademark without clearly identifying the compounding pharmacy that actually produced the medication. The FDA considers this a form of misbranding — patients couldn't tell who was actually making what they were injecting.

The Hims & Hers Backdrop

These warning letters didn't happen in isolation. Just weeks earlier, on February 6, 2026, the Department of Health and Human Services referred Hims & Hers Health to the Department of Justice for investigation — citing potential violations of the Federal Food, Drug, and Cosmetic Act and Title 18 (criminal) provisions. The same day, the FDA announced it would take "decisive steps" to restrict non-FDA-approved compounded GLP-1 drugs, naming Hims directly.

Hims had launched a compounded oral semaglutide pill and pulled it within days. Novo Nordisk followed with a lawsuit alleging unlawful mass-marketing of unapproved versions of Wegovy and Ozempic. Hims stock dropped 14% after hours.

The message to the telehealth industry was unmistakable: the era of regulatory permissiveness for compounded GLP-1 marketing is over.

What This Means for You as a Patient

If you're currently using a GLP-1 telehealth platform, these warning letters don't mean your medication is dangerous or that your provider is shutting down. Companies received 15 business days to correct their marketing. Most will comply. But the enforcement wave does highlight why provider verification matters more than ever.

Here's what to check:

• Does your provider clearly distinguish between compounded and FDA-approved medications on their website?
• Can you identify the compounding pharmacy that produces your medication by name?
• Is there a licensed prescriber with searchable NPI credentials reviewing your case?
• Has your provider received an FDA warning letter? You can search the FDA warning letter database at fda.gov.

Providers Not on the Warning List

The following telehealth platforms had no FDA warning letters on record as of May 2026 and maintain transparent practices around compounded medication sourcing: